This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsHumanCo Acquisition（HMCO）株式概要HumanCo Acquisition Corp. does not have significant operations. 詳細HMCO ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績2/6財務の健全性0/6配当金0/6報酬今年は黒字化を達成 リスク分析収益が 100 万ドル未満 ( $0 )マイナスの株主資本 負債は営業キャッシュフローで十分にカバーされていない 3年未満の財務データが利用可能 すべてのリスクチェックを見るHMCO Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$10.06該当なし内在価値ディスカウントEst. Revenue$PastFuture-13m14m2016201920222025202620282031Revenue US$1.0Earnings US$0AdvancedSet Fair ValueView all narrativesHumanCo Acquisition Corp. 競合他社C5 AcquisitionSymbol: NYSE:CXACMarket cap: US$177.8mPlum Acquisition IIISymbol: OTCPK:PLMJ.FMarket cap: US$82.9mSierra Lake AcquisitionSymbol: NasdaqCM:SIERMarket cap: US$379.5mPower & Digital Infrastructure Acquisition IISymbol: NasdaqGM:XPDBMarket cap: US$327.1m価格と性能株価の高値、安値、推移の概要HumanCo Acquisition過去の株価現在の株価US$10.0652週高値US$10.3052週安値US$9.73ベータ01ヶ月の変化0.40%3ヶ月変化1.31%1年変化1.72%3年間の変化n/a5年間の変化n/aIPOからの変化n/a最新ニュースお知らせ • Dec 03HumanCo Acquisition Corp.(NasdaqCM:HMCO) dropped from NASDAQ Composite IndexHumanco Acquisition Corp. has been removed from NASDAQ Composite Index .お知らせ • Nov 22HumanCo Acquisition Expects Nasdaq Will File A Form 25 with the United States Securities and Exchange Commission to Delist Its SecuritiesHumanCo Acquisition Corp. announced that, due to its anticipated inability to consummate an initial business combination within the time period required by its Amended and Restated Certificate of Incorporation, HumanCo Acquisition Corp. intends to dissolve and liquidate in accordance with the provisions of its Amended and Restated Certificate of Incorporation and will redeem all of the outstanding shares of Class A common stock that were included in the units issued in its initial public offering (the "Public Shares"), at a per-share redemption price of approximately $10.08. As of the close of business on December 1, 2022, the Public Shares will be deemed cancelled and will represent only the right to receive the redemption amount. In order to provide for the disbursement of funds from the trust account, the Company has instructed the trustee of the trust account to take all necessary actions to liquidate the trust account. The proceeds of the trust account will be held in a non-interest bearing account while awaiting disbursement to the holders of the Public Shares. Record holders may redeem their shares for their pro rata portion of the proceeds of the trust account by delivering their Public Shares to Continental Stock Transfer & Trust Company, the Company's transfer agent. Beneficial owners of Public Shares held in "street name," however, will not need to take any action in order to receive the redemption amount. The redemption of the Public Shares is expected to be completed within ten business days after December 1, 2022. The Company's initial stockholders have waived their redemption rights with respect to its outstanding common stock issued prior to the Company's initial public offering. There will be no redemption rights or liquidating distributions with respect to the Company's warrants, which will expire worthless. The Company expects that Nasdaq will file a Form 25 with the United States Securities and Exchange Commission (the "SEC") to delist its securities. The Company thereafter expects to file a Form 15 with the SEC to terminate the registration of its securities under the Securities Exchange Act of 1934, as amended.お知らせ • Nov 15HumanCo Acquisition Corp. announced delayed 10-Q filingOn 11/14/2022, HumanCo Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 29HumanCo Acquisition Receives Non-Compliance Notice from the Nasdaq Capital MarketHumanCo Acquisition Corp. (the "Company") announced that it has determined to restate its 2020 financial statements (the "Non-Reliance Period") in light of the U.S. Securities and Exchange Commission's (the "SEC") recently issued "Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies ("SPACs")" (the "Staff Statement"). This Staff Statement issued on April 12, 2021 informed market participants that warrants issued by SPACs and former SPACs may need to be reclassified as liabilities with non-cash fair value adjustments recorded in earnings at each reporting period. The Company had previously classified its issued warrants as equity. The Company currently expects that the reclassification of the warrants will have no impact on its historical liquidity, cash flows or revenues. Given the time and focus dedicated to the restatement process and the completion and filing of the Company's Form 10-K/A, the Company requires additional time to complete its customary quarterly review and reporting process and the filing of its Form 10-Q for the first quarter ended March 31, 2021 (the "Form 10-Q") and was unable to file the Form 10-Q by the May 17, 2021 deadline. As a result, the Company received a notice on May 28, 2021 from the Nasdaq Capital Market ("Nasdaq") indicating that the Company is not in compliance with the Nasdaq's continued listing requirements because it had not filed its Form 10-Q for the period ended March 31, 2021 with the SEC. The Form 10-Q will be filed as soon as is practicable after the filing of the Form 10-K/A.お知らせ • May 18HumanCo Acquisition Corp. announced delayed 10-Q filingOn 05/17/2021, HumanCo Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.最新情報をもっと見るRecent updatesお知らせ • Dec 03HumanCo Acquisition Corp.(NasdaqCM:HMCO) dropped from NASDAQ Composite IndexHumanco Acquisition Corp. has been removed from NASDAQ Composite Index .お知らせ • Nov 22HumanCo Acquisition Expects Nasdaq Will File A Form 25 with the United States Securities and Exchange Commission to Delist Its SecuritiesHumanCo Acquisition Corp. announced that, due to its anticipated inability to consummate an initial business combination within the time period required by its Amended and Restated Certificate of Incorporation, HumanCo Acquisition Corp. intends to dissolve and liquidate in accordance with the provisions of its Amended and Restated Certificate of Incorporation and will redeem all of the outstanding shares of Class A common stock that were included in the units issued in its initial public offering (the "Public Shares"), at a per-share redemption price of approximately $10.08. As of the close of business on December 1, 2022, the Public Shares will be deemed cancelled and will represent only the right to receive the redemption amount. In order to provide for the disbursement of funds from the trust account, the Company has instructed the trustee of the trust account to take all necessary actions to liquidate the trust account. The proceeds of the trust account will be held in a non-interest bearing account while awaiting disbursement to the holders of the Public Shares. Record holders may redeem their shares for their pro rata portion of the proceeds of the trust account by delivering their Public Shares to Continental Stock Transfer & Trust Company, the Company's transfer agent. Beneficial owners of Public Shares held in "street name," however, will not need to take any action in order to receive the redemption amount. The redemption of the Public Shares is expected to be completed within ten business days after December 1, 2022. The Company's initial stockholders have waived their redemption rights with respect to its outstanding common stock issued prior to the Company's initial public offering. There will be no redemption rights or liquidating distributions with respect to the Company's warrants, which will expire worthless. The Company expects that Nasdaq will file a Form 25 with the United States Securities and Exchange Commission (the "SEC") to delist its securities. The Company thereafter expects to file a Form 15 with the SEC to terminate the registration of its securities under the Securities Exchange Act of 1934, as amended.お知らせ • Nov 15HumanCo Acquisition Corp. announced delayed 10-Q filingOn 11/14/2022, HumanCo Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 29HumanCo Acquisition Receives Non-Compliance Notice from the Nasdaq Capital MarketHumanCo Acquisition Corp. (the "Company") announced that it has determined to restate its 2020 financial statements (the "Non-Reliance Period") in light of the U.S. Securities and Exchange Commission's (the "SEC") recently issued "Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies ("SPACs")" (the "Staff Statement"). This Staff Statement issued on April 12, 2021 informed market participants that warrants issued by SPACs and former SPACs may need to be reclassified as liabilities with non-cash fair value adjustments recorded in earnings at each reporting period. The Company had previously classified its issued warrants as equity. The Company currently expects that the reclassification of the warrants will have no impact on its historical liquidity, cash flows or revenues. Given the time and focus dedicated to the restatement process and the completion and filing of the Company's Form 10-K/A, the Company requires additional time to complete its customary quarterly review and reporting process and the filing of its Form 10-Q for the first quarter ended March 31, 2021 (the "Form 10-Q") and was unable to file the Form 10-Q by the May 17, 2021 deadline. As a result, the Company received a notice on May 28, 2021 from the Nasdaq Capital Market ("Nasdaq") indicating that the Company is not in compliance with the Nasdaq's continued listing requirements because it had not filed its Form 10-Q for the period ended March 31, 2021 with the SEC. The Form 10-Q will be filed as soon as is practicable after the filing of the Form 10-K/A.お知らせ • May 18HumanCo Acquisition Corp. announced delayed 10-Q filingOn 05/17/2021, HumanCo Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.株主還元HMCOUS Capital MarketsUS 市場7D-0.05%-0.3%1.1%1Y1.7%10.4%28.7%株主還元を見る業界別リターン: HMCO過去 1 年間で10.4 % の収益を上げたUS Capital Markets業界を上回りました。リターン対市場: HMCO過去 1 年間で28.7 % の収益を上げたUS市場を上回りました。価格変動Is HMCO's price volatile compared to industry and market?HMCO volatilityHMCO Average Weekly Movement0.2%Capital Markets Industry Average Movement3.6%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: HMCO 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: HMCOの 週次ボラティリティ ( 0% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2020n/aRoss Bermanir.humancospac.comもっと見るHumanCo Acquisition Corp. 基礎のまとめHumanCo Acquisition の収益と売上を時価総額と比較するとどうか。HMCO 基礎統計学時価総額US$386.68m収益（TTM）US$13.68m売上高(TTM)n/a28.3xPER（株価収益率0.0xP/SレシオHMCO は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計HMCO 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用-US$13.68m収益US$13.68m直近の収益報告Jun 30, 2022次回決算日該当なし一株当たり利益（EPS）0.36グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-2.9%HMCO の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2022/12/04 00:09終値2022/12/01 00:00収益2022/06/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋HumanCo Acquisition Corp. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Dec 03HumanCo Acquisition Corp.(NasdaqCM:HMCO) dropped from NASDAQ Composite IndexHumanco Acquisition Corp. has been removed from NASDAQ Composite Index .
お知らせ • Nov 22HumanCo Acquisition Expects Nasdaq Will File A Form 25 with the United States Securities and Exchange Commission to Delist Its SecuritiesHumanCo Acquisition Corp. announced that, due to its anticipated inability to consummate an initial business combination within the time period required by its Amended and Restated Certificate of Incorporation, HumanCo Acquisition Corp. intends to dissolve and liquidate in accordance with the provisions of its Amended and Restated Certificate of Incorporation and will redeem all of the outstanding shares of Class A common stock that were included in the units issued in its initial public offering (the "Public Shares"), at a per-share redemption price of approximately $10.08. As of the close of business on December 1, 2022, the Public Shares will be deemed cancelled and will represent only the right to receive the redemption amount. In order to provide for the disbursement of funds from the trust account, the Company has instructed the trustee of the trust account to take all necessary actions to liquidate the trust account. The proceeds of the trust account will be held in a non-interest bearing account while awaiting disbursement to the holders of the Public Shares. Record holders may redeem their shares for their pro rata portion of the proceeds of the trust account by delivering their Public Shares to Continental Stock Transfer & Trust Company, the Company's transfer agent. Beneficial owners of Public Shares held in "street name," however, will not need to take any action in order to receive the redemption amount. The redemption of the Public Shares is expected to be completed within ten business days after December 1, 2022. The Company's initial stockholders have waived their redemption rights with respect to its outstanding common stock issued prior to the Company's initial public offering. There will be no redemption rights or liquidating distributions with respect to the Company's warrants, which will expire worthless. The Company expects that Nasdaq will file a Form 25 with the United States Securities and Exchange Commission (the "SEC") to delist its securities. The Company thereafter expects to file a Form 15 with the SEC to terminate the registration of its securities under the Securities Exchange Act of 1934, as amended.
お知らせ • Nov 15HumanCo Acquisition Corp. announced delayed 10-Q filingOn 11/14/2022, HumanCo Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 29HumanCo Acquisition Receives Non-Compliance Notice from the Nasdaq Capital MarketHumanCo Acquisition Corp. (the "Company") announced that it has determined to restate its 2020 financial statements (the "Non-Reliance Period") in light of the U.S. Securities and Exchange Commission's (the "SEC") recently issued "Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies ("SPACs")" (the "Staff Statement"). This Staff Statement issued on April 12, 2021 informed market participants that warrants issued by SPACs and former SPACs may need to be reclassified as liabilities with non-cash fair value adjustments recorded in earnings at each reporting period. The Company had previously classified its issued warrants as equity. The Company currently expects that the reclassification of the warrants will have no impact on its historical liquidity, cash flows or revenues. Given the time and focus dedicated to the restatement process and the completion and filing of the Company's Form 10-K/A, the Company requires additional time to complete its customary quarterly review and reporting process and the filing of its Form 10-Q for the first quarter ended March 31, 2021 (the "Form 10-Q") and was unable to file the Form 10-Q by the May 17, 2021 deadline. As a result, the Company received a notice on May 28, 2021 from the Nasdaq Capital Market ("Nasdaq") indicating that the Company is not in compliance with the Nasdaq's continued listing requirements because it had not filed its Form 10-Q for the period ended March 31, 2021 with the SEC. The Form 10-Q will be filed as soon as is practicable after the filing of the Form 10-K/A.
お知らせ • May 18HumanCo Acquisition Corp. announced delayed 10-Q filingOn 05/17/2021, HumanCo Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Dec 03HumanCo Acquisition Corp.(NasdaqCM:HMCO) dropped from NASDAQ Composite IndexHumanco Acquisition Corp. has been removed from NASDAQ Composite Index .
お知らせ • Nov 22HumanCo Acquisition Expects Nasdaq Will File A Form 25 with the United States Securities and Exchange Commission to Delist Its SecuritiesHumanCo Acquisition Corp. announced that, due to its anticipated inability to consummate an initial business combination within the time period required by its Amended and Restated Certificate of Incorporation, HumanCo Acquisition Corp. intends to dissolve and liquidate in accordance with the provisions of its Amended and Restated Certificate of Incorporation and will redeem all of the outstanding shares of Class A common stock that were included in the units issued in its initial public offering (the "Public Shares"), at a per-share redemption price of approximately $10.08. As of the close of business on December 1, 2022, the Public Shares will be deemed cancelled and will represent only the right to receive the redemption amount. In order to provide for the disbursement of funds from the trust account, the Company has instructed the trustee of the trust account to take all necessary actions to liquidate the trust account. The proceeds of the trust account will be held in a non-interest bearing account while awaiting disbursement to the holders of the Public Shares. Record holders may redeem their shares for their pro rata portion of the proceeds of the trust account by delivering their Public Shares to Continental Stock Transfer & Trust Company, the Company's transfer agent. Beneficial owners of Public Shares held in "street name," however, will not need to take any action in order to receive the redemption amount. The redemption of the Public Shares is expected to be completed within ten business days after December 1, 2022. The Company's initial stockholders have waived their redemption rights with respect to its outstanding common stock issued prior to the Company's initial public offering. There will be no redemption rights or liquidating distributions with respect to the Company's warrants, which will expire worthless. The Company expects that Nasdaq will file a Form 25 with the United States Securities and Exchange Commission (the "SEC") to delist its securities. The Company thereafter expects to file a Form 15 with the SEC to terminate the registration of its securities under the Securities Exchange Act of 1934, as amended.
お知らせ • Nov 15HumanCo Acquisition Corp. announced delayed 10-Q filingOn 11/14/2022, HumanCo Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 29HumanCo Acquisition Receives Non-Compliance Notice from the Nasdaq Capital MarketHumanCo Acquisition Corp. (the "Company") announced that it has determined to restate its 2020 financial statements (the "Non-Reliance Period") in light of the U.S. Securities and Exchange Commission's (the "SEC") recently issued "Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies ("SPACs")" (the "Staff Statement"). This Staff Statement issued on April 12, 2021 informed market participants that warrants issued by SPACs and former SPACs may need to be reclassified as liabilities with non-cash fair value adjustments recorded in earnings at each reporting period. The Company had previously classified its issued warrants as equity. The Company currently expects that the reclassification of the warrants will have no impact on its historical liquidity, cash flows or revenues. Given the time and focus dedicated to the restatement process and the completion and filing of the Company's Form 10-K/A, the Company requires additional time to complete its customary quarterly review and reporting process and the filing of its Form 10-Q for the first quarter ended March 31, 2021 (the "Form 10-Q") and was unable to file the Form 10-Q by the May 17, 2021 deadline. As a result, the Company received a notice on May 28, 2021 from the Nasdaq Capital Market ("Nasdaq") indicating that the Company is not in compliance with the Nasdaq's continued listing requirements because it had not filed its Form 10-Q for the period ended March 31, 2021 with the SEC. The Form 10-Q will be filed as soon as is practicable after the filing of the Form 10-K/A.
お知らせ • May 18HumanCo Acquisition Corp. announced delayed 10-Q filingOn 05/17/2021, HumanCo Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
